Anti-FcεRI autoantibody and other mast cell activation-related molecules
in Crohn’s disease
Background: The diagnosis of Crohn’s disease (CD) is still challenging,
and the search for novel biomarkers is a worthwhile endeavor. Mast cells
can be activated in various ways. Whether serum IgE, anti-IgE and
anti-IgE high-affinity receptor (FcεRI) antibodies are involved in the
pathogenesis of CD was investigated by bridging FcεRI to activate MCs.
The relationship between MCs and CD is also explored in this
research.Methods: Microplates with human FcεRIα were coated and an
enzyme-labeled anti-human IgG was used as the tracer to successfully
establish an indirect enzyme-linked immunosorbent assay (ELISA) method
for semi-detection of IgG anti-FcεRI. The optimal working conditions
were explored, followed by conducting the method evaluation. The serum
samples and clinical data of 117 CD patients and 75 healthy controls
were collected. IgE was measured by the rate turbidity turbidimetry; IgG
anti-IgE and IgG anti-FcεRI were detected by ELISA. IgG anti-pancreatic
antibody (PAB) and anti-Saccharomyces cerevisiae antibody (ASCA) were
determined by indirect immunofluorescence assay. Data were analyzed
concerning the clinical characteristics.Conclusions: An ELISA for the
detection of anti-FcεRI was established and validated, which may
contribute to facilitating the study of mast cell-related diseases.
Anti-FcεRI positive CD patients were associated with adverse phenotypes,
suggesting its value in the diagnosis and management of CD.